EU trade deal threatens access to life saving drugs for developing countries

Mar 22, 2011

A new trade agreement between India and Europe would block access to life saving drugs for billions of people living in developing countries, warns an expert in the British Medical Journal today.

The EU wants India to adopt tough new rules for drugs so that no new generic drug could be sold in India without the permission of the company that owned the brand name version of the drug, writes James Love at Knowledge Ecology International in an editorial.

Not only would this have an enormous impact on the entire , it would also dramatically shrink the global market for inexpensive , warns Love.

It will also make a mockery of promises made by EU trade officials that governments would implement intellectual property rules in such a way to "protect public health and, in particular, to promote access to medicines for all."

In 1970, India eliminated patents on drug products, which enabled it to develop a strong generic drug industry. In 2005, India modified its patent law, to conform to the (WTO) rules on the protection of intellectual property. But in doing so, India provide certain safeguards to make it easier to continue to manufacture generic medicines.

Now Europe wants India to adopt strict intellectual property protection rules that go beyond its obligations at the WTO, and which will effectively remove India as a legal market for early production of generic drugs. It will also restrict other access to much-needed supplies of affordable drugs.

Furthermore, the EU is currently negotiating this agreement with India in secret, despite its potential impact on billions of people living in developing countries, writes the author.

"Political and civic leaders from Europe and around the world must appeal to the EU to avoid outcomes that make it even more difficult to manufacture and market inexpensive drugs in developing countries," argues Love. "This can begin by eliminating demands that India adopt exclusive rights on drug test data, or lower its standards for granting patents on medical inventions."

Explore further: Anti-cholinergic drugs impair physical function in elderly patients

add to favorites email to friend print save as pdf

Related Stories

EU-India trade deal could limit generics supply

Dec 10, 2010

(AP) -- AIDS patients in Africa are nervously awaiting the outcome of talks launched Friday between Europe and India on a new trade deal that could slash the world's supply of cheap generics.

European office withdraws Nexium patent

Dec 21, 2006

The European Patent Office, answering a generic drug maker's challenge, withdrew a patent on Britain-based AstraZeneca PLC's heartburn treatment, Nexium.

Recommended for you

FDA to start regulating lab-developed tests

Jul 31, 2014

(AP)—The Food and Drug Administration announced Thursday it will begin regulating laboratory-developed tests, a growing class of medical diagnostics that have never before been subject to federal oversight.

Determine patient preferences by means of conjoint analysis

Jul 29, 2014

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

User comments : 0